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Vitamin D receptorHereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is caused by mutations in the VDR gene, and its
inheritance is autosomal recessive. In this report, we aimed to conﬁrmwhether HVDRR is occasionally inherited
as a dominant trait. An 18-month-old Japanese boy was evaluated for short stature and bowlegs. His father had
been treated for rickets during childhood, and his paternal grandfather had bowlegs. We diagnosed him with
HVDRRbased on laboratory data and radiographic evidence of rickets. Sequence analyses ofVDRwereperformed,
and the functional consequences of the detected mutations were analyzed for transcriptional activity, ligand
binding, and interaction with the retinoid X receptor, cofactors, and the vitamin D response element (VDRE). A
novel mutation (Q400LfsX7) and a reported variant (R370H) were identiﬁed in the patient. Heterozygous
Q400LfsX7 was detected in his father, and heterozygous R370H was detected in his healthy mother. Functional
studies revealed that the transcriptional activity of Q400LfsX7-VDR was markedly disturbed. The mutant had a
dominant-negative effect on wild-type-VDR, and the ligand binding afﬁnity of Q400LfsX7-VDR was completely
impaired. Interestingly, Q400LfsX7-VDR had a strong interaction with corepressor NCoR and could interact
with VDRE without the ligand. R370H-VDR was functionally similar to wild-type-VDR. In conclusion, we found
a dominant-negativemutant of VDR causing dominantly inherited HVDRR through a constitutive corepressor in-
teraction, a mechanism similar to that in dominantly inherited thyroid hormone receptor mutations. Our report
together with a reported pedigree suggested a distinct inheritance of HVDRR and enriched our understanding of
VDR abnormalities.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The hormonal metabolite of vitamin D, 1,25-dihydroxyvitamin D
[1,25(OH)2D3] regulates calcium homeostasis, cellular differentiation,
and immune function through its binding to the vitamin D receptor
(VDR), a transcription factor belonging to the steroid/nuclear receptor
superfamily (Feldman and Malloy, 2014; Haussler et al., 2013; Rachez
and Freedman, 2000; Malloy et al., 2011). The regulation of speciﬁc
gene transcription by VDR requires it to form a heterodimer with the
retinoid X receptor (RXR); this heterodimer then binds to vitamin D
response elements (VDREs) in the promoter region of target genes, re-
leasing corepressor proteins and recruiting coactivator proteins.
1,25(OH)2D3 binding to VDR causes the repositioning of helix H12,
which contains an activation function 2 (AF-2) domain, allowing for
the recruitment of coactivators (Rochel et al., 2000).. This is an open access article underHereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR)
(OMIM #277440), also known as vitamin D-resistant rickets type 2A,
is a rare monogenic disorder caused by mutations in the VDR gene
(Malloy and Feldman, 2010). Patients with HVDRR often have consan-
guinity in the family and display a number of clinical features including
early onset rickets, hypocalcemia, and secondary hyperparathyroidism.
Moreover, they have signiﬁcantly elevated serum 1,25(OH)2D levels;
this differentiates this condition from 1α-hydroxylase deﬁciency, also
known as vitamin D-dependent rickets type 1A (Kitanaka et al., 1998).
Multiple mutations in the VDR gene have been reported to cause
HVDRR (Malloy et al., 2014). Mutations in the DNA binding domain
(DBD) of the VDR gene interfere with VDR–DNA interactions and result
in the loss of VDR function, and these are usually associated with alope-
cia (Malloy et al., 2014). Mutations in the VDR ligand binding domain
(LBD) alter the ligand binding afﬁnity in variousways. These LBDmuta-
tions can result in partial or total hormone unresponsiveness and can be
associated with alopecia (Malloy et al., 2002).
Patients with HVDRR usually have biallelic mutations in the VDR
gene (Feldman and Malloy, 2014). Those with heterozygous mutationsthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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development (Malloy et al., 2004, 2011). Recently, a single family has
been reported to demonstrate dominant inheritance caused by a VDR
mutation with a dominant-negative effect (Malloy et al., 2011). Here,
we report a family with HVDRR showing dominant inheritance, in
which we identiﬁed a novel mutation with a dominant-negative effect
and enhanced corepressor interaction. This is the ﬁrst report of a
dominant-negative VDR mutation demonstrating a constitutive core-
pressor interaction, amechanismsimilar to that in dominantly inherited
thyroid hormone receptor (TR) mutations (Safer et al., 1998; Liu et al.,
1998; Fozzatti et al., 2011, 2013; Bochukova et al., 2012).
2. Subjects and methods
2.1. Patient clinical observation
An 18-month-old Japanese boy was referred to our institute and
evaluated for short stature and bowlegs. His body length and weight
were 80.2 cm [−2.0 standard deviations (SD)] and 8.6 kg (−1.6 SD), re-
spectively. He is the ﬁrst child of nonconsanguineous parents, and his
birth history was unremarkable. He started walking at the age ofA
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Fig. 1. Radiograph of the patient, a chromatogram of the novel mutation, and the family tree. (A
that the patient had evident rickets. (B) The novel p.Q400LfsX7 mutation. In the chromatogram
lower part shows the subcloned normal and mutant sequences. (C) The pedigree analysis in th14months, but his parents felt he had a slightwaddling gait. Intellectual
developmentwaswithin normal limits. His father had been treated for a
short period with some vitamin D for rickets during childhood, which
was considered to be due to simple vitamin D deﬁciency; his height
was 173 cm, and he had a slight bowing of his legs. The patient's pater-
nal grandfather also had bowlegs without alopecia, although he had
never been treated.
Radiographic study of thehands andkneeswas consistentwith rickets
(Fig. 1A). Blood biochemistry showed normal serum calcium (Ca)
(2.2mmol/l; reference range, 2.1–2.4) and 25(OH)D levels (20 ng/ml; in-
sufﬁciency, b20). However, they showed slightly decreased serum phos-
phorus (P) (1.1 mmol/l; reference range, 1.3–2.0) and elevated serum
alkaline phosphatase (ALP) (3346 U/l; reference range, 171–785), intact
parathyroid hormone (iPTH) (480 pg/ml; reference range, 10–65), and
1,25(OH)2D levels (304 pg/ml; reference range, 20–70). On the basis of
these ﬁndings of obvious rickets, with elevated 1,25(OH)2D, ALP, and
iPTH levels and a normal 25(OH)D level, we diagnosed him with
HVDRR. However, we could not exclude the possibility of vitamin D deﬁ-
ciency. He was effectively treated with 2 μg alfacalcidol daily without any
calcium supplements, and his rickets, ALP, iPTH levels improved. The dose
was tapered and stopped at the age of 4 years. At the last follow-up (age,p.Q400LfsX7
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) Radiograph of the patient at diagnosis. It showed cupping, fraying and ﬂaring indicating
: nucleotides in bold black letters with underline indicate an 8-base pair deletion; and the
is study.
70 T. Isojima et al. / Bone Reports 2 (2015) 68–735 years and11months), he hadneither rickets nor alopecia andmeasured
106.8 cm (−1.3 SD) in height. His blood biochemistry showed normal Ca
(2.4 mmol/l), P (1.5 mmol/l), ALP (622 U/l), and iPTH (53 pg/ml), but
elevated 1,25(OH)2D (271 pg/ml) levels.
2.2. VDR gene analysis
We obtained informed consent for DNA analysis from the parents,
and the Ethics Committee of The University of Tokyo approved the
study. Genomic DNA was extracted from peripheral white blood cells
using a QIAampDNA BloodMidi Kit (Qiagen, Hilden, Germany). The en-
tire coding region and exon–intron boundaries of the VDR gene were
ampliﬁed from genomic DNA by polymerase chain reaction (PCR)
using the designed PCR primers. The details of the primers and the
PCR conditionswill be provided on request. Subsequently, PCR products
were sequenced using an ABI Prism BigDye Terminator Cycle Sequenc-
ing Ready Reaction Kit (PE Applied Biosystems, Foster City, CA) and the
forward and reverse primers from the PCR ampliﬁcation. Direct se-
quencing in both directions was performed on an autosequencer (ABI
PRISM 310, Genetic Analyzer; Applied Biosystems). Detected mutations
were conﬁrmed by cloning the PCR products into the pCR 2.1 vector
using a TOPOTACloning kit (Invitrogen, Carlsbad, CA, U.S.A.). The clones
derived from both alleles were sequenced.
2.3. Construction of plasmids
Expression plasmids for wild-type full-length human VDR or RXRα
and a reporter plasmid for human 24-hydroxylase promoter (−367 to
0) in pGL3 were provided by S. Kato. The expression plasmids hVDR-
pCMX, hVDR-ﬂag-pCMX, hVDR-VP16-pCMX, RXRα-GAL4-pCMX,
GRIP1-GAL4-pCMX, and NCoR-GAL4-pCMX have been reported previ-
ously (Inaba et al., 2007). GAL4-responsive MH100(UAS)x4-tk-LUC and
VDR-responsive Sppx3-tk-LUC were also used in the luciferase reporter
assay (Nakano et al., 2005; Igarashi et al., 2007). The mutant plasmids
(Q400LfsX7 and R370H) were created with a Quick Change Site-
directed mutagenesis kit (Stratagene, La Jolla, CA) according to the
manufacturer's protocol (Sato et al., 2005). VDRmutant constructs were
sequence-veriﬁed to have no extra mutations.
2.4. Transcriptional activity
COS-1 cells were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum, 100 unit/ml pen-
icillin, and 100 μg/ml streptomycin at 37 °C in a humidiﬁed atmosphere
containing 5% CO2. Transfections in COS-1 cells were performed by
modiﬁcation of previously reported methods (Sato et al., 2005;
Jurutka et al., 2000). Cells that were cultured in 24-well plates were
transfected with 800 ng DNA, including 300 ng 24-hydroxylase-pGL3
promoter luciferase, the indicated amounts of each human VDR expres-
sion plasmids, and 1 ng pRL-CMV (Promega, Madison, WI) using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Four hours after trans-
fection, the indicated amounts of ligand were added. After 24 h, tran-
scriptional activity was assayed using a Dual-Luciferase Reporter Assay
System (Promega). The luciferase activities of human 24-hydroxylase
promoter luciferase plasmidwere normalized to the luciferase activities
of pRL-CMV. Transient transfections were performed in triplicate, and
each experiment was repeated at least three times.
2.5. Mammalian two-hybrid analyses
Human embryonic kidney (HEK) 293 cells were cultured in DMEM
containing 5% fetal bovine serum and an antibiotic–antimycotic
(Nacalai, Kyoto) at 37 °C in a humidiﬁed atmosphere containing 5%
CO2. Transfections in HEK293 cells were performed by the calcium
phosphate coprecipitation analysis as described previously (Adachi
et al., 2005). Cells that were cultured in 96-well plates were transfectedwith 50 ng GAL4-responsive MH100(UAS)x4-tk-LUC reporter plasmid
or VDR-responsive Sppx3-tk-LUC, 20 ng β-galactosidase-pCMX, 15 ng
of each VDR, and/or the cofactor expression plasmid and pGEM carrier
DNA for a total 150 ng DNA. Eight hours after transfection, the indicated
amounts of ligands were added. Cells were harvested approximately
16–24 h after treatment, and luciferase and β-galactosidase activities
were assayed using a luminometer and a microplate reader (Molecular
Devices, Sunnyvale, CA). Luciferase data were normalized to an internal
β-galactosidase control and were represented as the mean (±SD) of
triplicate assays.
2.6. Competitive ligand-binding assay
LBDs of humanVDR and itsmutants were cloned into theGST-fusion
vector pGEX-4T1 (Amersham Pharmacia Biotech, Piscataway, NJ). GST–
VDR fusion proteins were expressed in BL21 DE3 cells (Promega) and
puriﬁed with glutathione sepharose beads (Amersham Pharmacia Bio-
tech). A competitive ligand-binding assay was performed by modiﬁca-
tion of previously reported methods (Nakajima et al., 1994; Solomon
et al., 2001). Brieﬂy, 500 ng GST fusion proteinswere bound to glutathi-
one sepharose and incubated with [26,27-methyl-3H]1α,25(OH)2D3
(Amersham Pharmacia Biotech) in the presence or absence of the non-
radioactive ligand in a buffer (10 mM Tris–HCl, pH 7.6; 1 mM EDTA;
300 mM KCl; 1 mM dithiothreitol; 10% glycerol) for 3 h at 4 °C. After
washing twice, the protein and bound1α,25(OH)2D3were resuspended
in 200 μl of the binding buffer, and a 150 μl sample was assessed by
liquid scintillation counting.
3. Results
3.1. Mutation analysis of the VDR gene
The genomic analyses for the VDR gene revealed that the patient had
a novel deletion mutation and a reported variant (rs202139940). The
mutation is an 8-base pair deletion in exon 10 of the VDR gene,
c.1199–1206 del, p.Q400LfsX7, which is predicted to result in a frame-
shift from codon 400 and premature termination just before helix H12
(Fig. 1B). This detected mutation was heterozygous in his father. The
variant (rs202139940) is a GNA transition in exon 10 of the VDR gene,
which is predicted to result in a substitution of arginine to histidine in
codon 370 (R370H). This variant was also found to be heterozygous in
his healthymother. Both the patient and his mother were heterozygous
for the FokI polymorphism (F/f) that alters the translational site from
M1 to M4 (Jurutka et al., 2000; Haussler et al., 1998), while his father
was homozygous for the f/M1 alleles.
3.2. Transcriptional activity of Q400LfsX7-VDR and R370H-VDR
To examine whether the detected Q400LfsX7 mutation and the
R370H variant can affect VDR transactivation, wild-type Q400LfsX7-
VDR and R370H-VDR were transiently overexpressed in COS-1 cells,
and transcriptional activity was analyzed using the reporter 24-
hydroxylase promoter. R370H-VDR showed similar transcriptional
activity to that of wild-type-VDR (Fig. 2A). However, Q400LfsX7-VDR
had negligible transcriptional activity. Similar results were also ob-
served in HEK293 cells (data not shown). These results indicated that
the Q400LfsX7-VDR mutant had completely lost all transcriptional
activities, whereas R370H remained normal.
3.3. The dominant-negative effect of Q400LfsX7-VDR on wild-type VDR
Wehypothesize that the heterozygous Q400LfsX7mutationwas the
molecular cause of his HVDRR.We examined the dominant-negative ef-
fect of Q400LfsX7-VDR on the wild-type product by increasing the
mutant-to-wild-type protein ratio with 5 nM of 1,25(OH)2D3. When
equal amounts of wild-type VDR and Q400LfsX7-VDR proteins were
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Fig. 2. Functional analysis of the VDRmutants. (Luciferase activity of the reporter is shown
as relative light unit compared to that in cells transfected with control vector and treated
with vehicle control. Error bars represent one standard deviation. (*) and (**) denote the
statistically signiﬁcant difference comparing to wild-type VDR at p b 0.05 and p b 0.01, re-
spectively). (A) The transcriptional activity of Q400LfsX7 or R370H-VDR in COS-1
transfected cells. (B) Analysis of the dominant-negative effect of Q400LfsX7-VDR
on wild-type-VDR transcriptional activity in COS-1 transfected cells with 5 nM of
1,25(OH)2D3. (C) Direct binding of 1,25(OH)2D3 to VDR. GST–VDR fusion proteins or
GST control proteins incubated with increasing concentrations of [3H]1,25(OH)2D3 in
the presence or absence of 400-fold excess nonradioactive 1,25(OH)2D3.
71T. Isojima et al. / Bone Reports 2 (2015) 68–73expressed, transcriptional activity was reduced by approximately
50%, and the increasing amounts of the mutant VDR further re-
pressed wild-type VDR transcriptional activity (Fig. 2B). This ﬁnding
demonstrated that Q400LfsX7-VDR had a dominant-negative effect
on wild-type VDR. However, R370H-VDR did not affect wild-type
VDR transcriptional activity (Fig. 2B). Moreover, Q400LfsX7-VDR
showed a dominant-negative effect on R370H-VDR activity, similar
to its effect on wild-type-VDR (data not shown). Similar results
were observed in HEK293 cells using VDR-responsive Sppx3-tk-
LUC (data not shown).3.4. Ligand binding ability of Q400LfsX7-VDR and R370H-VDR
The binding afﬁnity of 1,25(OH)2D3 of Q400LfsX7 or R370H-VDR
was examined by the competitive binding assay. Isotopically labeled
1,25(OH)2D3 was incubated with glutathione-S-transferase (GST)–
VDR proteins in the presence or absence of excess unlabeled
1,25(OH)2D3, and speciﬁc binding of 1,25(OH)2D3 was calculated.
[3H]1,25(OH)2D3 effectively bound to wild-type-VDR and R370H-
VDR but did not bind to Q400LfsX7-VDR. This result indicated thatligand binding afﬁnity of Q400LfsX7-VDR was completely impaired
(Fig. 2C).
3.5. Interaction with RXR, coactivator, and corepressor of Q400LfsX7-VDR
and R370H-VDR
Interactions between VDR mutants, RXR, the coactivator, or the
corepressor were analyzed by a mammalian two-hybrid assay
using hVDR-VP16-pCMX, RXRα-GAL4-pCMX, GRIP1-GAL4-pCMX, and
NCoR-GAL4-pCMX, respectively. HEK293 cells were cotransfected
with hVDR-VP16-pCMX, the MH100(UAS)x4-tk-LUC reporter, and
RXRα-GAL4-pCMX and were treated with increasing concentrations of
1,25(OH)2D3. R370H-VDR interacted with RXRα, similar to wild-type-
VDR, in a dose-dependent manner of the ligand. However, Q400LfsX7-
VDR did not interact with RXRα (Fig. 3A). This ﬁnding suggested that
Q400LfsX-VDR had impaired heterodimerization with RXR. Next,
we analyzed the interaction with a coactivator, GRIP1 (Fig. 3B).
1,25(OH)2D3 induced concentration-dependent associations of GRIP1
with wild-type or R370H-VDR. On the other hand, the association of
Q400LfsX7-VDR with GRIP1 was not identiﬁed in any amounts of
1,25(OH)2D3 (Fig. 3B). Then, the interaction of VDR with a corepressor,
NCoR, was evaluated with similar experiments (Fig. 3C). Wild-type or
R370H-VDR showed an interaction with NCoR in the absence of the
ligand, which decreased by adding 1,25(OH)2D3. In contrast,
Q400LfsX7-VDR had a strong interaction with NCoR, which did not
decrease by adding 1,25(OH)2D3 (Fig. 3C). These data indicated that
Q400LfsX7 displayed a defective release of NCoR in response to the
ligand.
3.6. VDRE interactions with Q400LfsX7-VDR or R370H-VDR
We next assessed the interaction of the VDR mutants and VDRE by
transfecting VP16-VDR chimeric receptors together with the VDRE re-
porter. Because of ligand-independent activity, the luciferase activities
of VP16 chimeric receptors showed an interaction between the receptor
and the binding element (Makishima et al., 2002; Adachi et al., 2004;
Endo-Umeda et al., 2012). HEK293 cells were transfected with VP16-
VDR chimeric mutants together with the luciferase reporter containing
a VDR-responsive everted repeat-6 element from the CYP3A4 promoter
(Makishima et al., 2002). The activity was compared with the activity of
those without VP16 to differentiate from transcriptional activity. Wild-
type VP16-VDR or VP16-R370H-VDR induced luciferase activities in
the absence of the ligand, and adding the ligand increased the activity
(compare Fig. 3D lanes 5–12 with Fig. 3E lanes 5–12). This result sug-
gested that these VDRs interacted with VDRE without the ligand and
had ligand-dependent enhancement. In contrast, VP16-Q400LfsX7-
VDR had ligand-independent activity (compare Fig. 3D lanes 13–16
with Fig. 3E lanes 13–16). Thus, Q400LfsX7-VDR could interact with
VDRE, although the interaction was not inﬂuenced by the ligand
(Fig. 3D lanes 13–16).
4. Discussion
We have identiﬁed and presented a novel VDR mutation
(Q400LfsX7) with a dominant negative effect on wild-type-VDR in a
family with dominantly inherited HVDRR. Because HVDRR is usually
transmitted autosomal recessively, and because our patient had the
R370H variant, we initially believed that the mutation and the variant
were the molecular basis for his HVDRR. However, when we assessed
the functionality of R370H [using the Sorting Intolerant from Tolerant
(SIFT) web-based tool (http://sift.jcvi.org) and the Polymorphism Phe-
notyping 2 (PolyPhen2) tool (http://genetics.bwh.harvard.edu/pph2)]
by homologymodeling and threading, R370Hwas described as “tolerat-
ed” and “benign,” respectively. Furthermore, considering that rickets
was dominantly inherited in this family (Fig. 1C), and that the patient
showed a clinical course similar to that shown by his father, who had
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this mutation was the more likely molecular cause of his HVDRR. In-
deed, the function of R370H-VDR was almost identical to wild-type
VDR, including its transcriptional activity, ligand binding, and interac-
tions with RXR, cofactors, and VDRE (Figs. 2–3). Conversely, transcrip-
tional activity and ligand binding ability of Q400LfsX7-VDR were
completely impaired (Fig. 2A and C). More importantly, the mutant
had a dominant-negative effect on wild-type-VDR (Fig. 2B). Thus, we
concluded that the heterozygous Q400LfsX7 mutation caused the dom-
inantly inherited HVDRR in this family through its dominant-negative
effect on wild-type-VDR.
To our knowledge, this is the second reported pedigree of dominant-
ly inherited HVDRR. The mutation detected in the ﬁrst reported family
(E420A) has been reported to show a dominant-negative effect
(Malloy et al., 2011). In this study, we found that our Q400LfsX7mutant
differed from that in the previous report in terms of several functional
properties. First, ligand binding was completely abolished in
Q400LfsX7 (Fig. 2C), but remained in the E420A mutant. Second,
Q400LfsX7 did not interact with RXR (Fig. 3A), while E420A could
bind with RXR (Malloy et al., 2011). Third and importantly, our mutant
strongly interacted with NCoR (Fig. 3C). Fourth, we demonstrated that
Q400LfsX7 could interact with VDRE (Fig. 3D). Theseﬁndings suggested
that the dominant-negative effect of Q400LfsX7 was caused by aconstitutive interaction with NCoR that may interact with VDRE to in-
hibit the activity of liganded wild-type-VDR. It is interesting that a sim-
ilarmolecularmechanismwas postulated in the syndrome of resistance
to thyroid hormone (RTH) caused bymutations in the TRα and β genes
(THRA and THRB, respectively) (Safer et al., 1998; Liu et al., 1998;
Fozzatti et al., 2011, 2013; Bochukova et al., 2012). In contrast to
HVDRR, RTH is usually an autosomal dominant disease. This dominant
inheritance had been attributed to the dominant-negative effect of mu-
tant THRA or THRB by failing to dissociate with NCoR (Safer et al., 1998;
Fozzatti et al., 2011; Bochukova et al., 2012; Refetoff et al., 1993;
Jameson, 1994). Most interestingly, the THRA E403X mutant lacks
helix H12 and has similarly enhanced corepressor interaction and ab-
sent ligand binding through its loss of amino acids critical for hormone
binding and coactivator recruitment, as shown by crystallographic
modeling (Bochukova et al., 2012). We speculated that Q400LfsX7-
VDR also caused an inability to release a corepressor by exposing a hy-
drophobic cleft on the receptor surface through the loss of helix H12.
These ﬁndings suggested that HVDRR may be inherited as a dominant
trait if the mutant has a constitutive corepressor interaction causing a
dominant-negative effect, similar to RTH defects.
It is notable that our patient did not have alopecia. Cumulative data
indicate that functional VDR is required for hair growth, and that alope-
cia is unrelated to the calcium or metabolic abnormalities that cause
73T. Isojima et al. / Bone Reports 2 (2015) 68–73rickets (Malloy and Feldman, 2011). In addition, previous data indicate
that VDR mutations cause defects in DNA binding, and that RXR
heterodimerization or the absence of VDR causes alopecia, and muta-
tions that alter VDR afﬁnity for 1,25(OH)2D3 or disrupt coactivator inter-
actions do not cause alopecia (Malloy and Feldman, 2011). Our ﬁnding
suggested that, although Q400LfsX7-VDR did not interact with RXR,
the mutant did not affect its dominant-negative effect on wild-type-
VDR for the regulation of the hair cycle. A possible explanation is that
Q400LfsX7-VDR may not be overexpressed compared with wild-type-
VDR in the hair follicle. Further research using this mutant is necessary
to elucidate the role of VDR in hair growth and differentiation.
Our results suggested that some patients with vitamin D-deﬁcient
rickets may have a VDR mutation. Our patient had obvious rickets and
short stature but did not have hypocalcemia. His symptoms were rela-
tively mild when compared with the classic clinical pattern of HVDRR,
and his clinical course that the medication could be stopped by
4 years of age was similar to that of vitamin D-deﬁcient rickets. In fact,
his fatherwas treatedwith vitamin D under themisdiagnosis of vitamin
D-deﬁcient rickets. In addition, aside from bowlegs, his unexamined pa-
ternal grandfather was otherwise asymptomatic without medication.
The resolution of vitamin D resistance in patients with HVDRR has
been previously described, but it typically occurs around puberty
(Tiosano et al., 2011). We consider that mild cases of HVDRR may be
misdiagnosed as vitamin D deﬁciency or remain undiagnosed. Our re-
sults expand the concept of HVDRR and enrich our understanding of
VDR function in the pathogenesis of HVDRR.
5. Conclusion
We identiﬁed a novel VDRmutation (Q400LfsX7) with a dominant-
negative effect on wild-type VDR in a family with dominantly inherited
HVDRR, andwe clariﬁed that themutant interacted stronglywith NCoR.
Theseﬁndings suggested a distinct inheritance of HVDRR that expanded
our understanding of the condition. Further investigations and pedigree
analyses are needed to reveal the mechanism underlying dominantly
inherited HVDRR.
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